<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2169">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05132920</url>
  </required_header>
  <id_info>
    <org_study_id>NCH-201803</org_study_id>
    <secondary_id>2021-000732-54</secondary_id>
    <nct_id>NCT05132920</nct_id>
  </id_info>
  <brief_title>Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhage</brief_title>
  <acronym>FINISHER</acronym>
  <official_title>Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmacy of the University Hospital Leipzig- AöR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>nextevidence GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aneurysmal subarachnoid hemorrhage (SAH) is a fatal disease with high morbidity and&#xD;
      mortality. While the primary injury results from the initial bleeding and cannot be&#xD;
      influenced, secondary injury through vasospasms and delayed cerebral ischemia (DCI) during&#xD;
      the course of the disease might be a target for intervention in order to improve outcome. To&#xD;
      date, beside the aneurysm treatment to prevent re-bleeding and the administration of oral&#xD;
      nimodipine, there is no causal therapy available, so that novel treatment concepts are&#xD;
      desperately needed. There are strong indications that inflammation contributes to DCI and&#xD;
      therefore poor outcome and plays a major role in SAH. Some studies suggest a beneficial&#xD;
      effect of anti-inflammatory drugs like glucocorticoids (GC) in SAH patient, but there are no&#xD;
      data from randomized controlled trials proving or disproving the beneficial effect of GC, so&#xD;
      that current guidelines do not recommend the use of GC in SAH so far.&#xD;
&#xD;
      This multi-center trial aims to generate the first confirmatory data in a controlled&#xD;
      randomized fashion that dexamethasone (DEX) improves the outcome in a clinically relevant&#xD;
      endpoint in SAH patients. Moreover, this trial will generate first data in a secondary&#xD;
      analysis, whether the initial inflammatory state of SAH patients defines a subgroup that&#xD;
      particularly responds to a treatment with DEX.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>modified Rankin Scale (mRS) at 6 months after SAH</measure>
    <time_frame>6 months</time_frame>
    <description>Dichotomized modified Rankin Scale (mRS) 6 months after subarachnoid haemorrhage. The dichotomization will be done in the classes &quot;favourable&quot; (mRS 0-3) versus &quot;unfavourable &quot; (mRS 4-6) outcome.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">334</enrollment>
  <condition>Aneurysmal Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 x 8 mg (2 ml) dexamethasone daily for days 1-7 and 1 x 8 mg (2 ml) dexamethasone daily for days 8-21 in addition to aneurysm treatment and best medical intensive care of SAH patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 x 2 ml Placebo daily for days 1-7 and 1 x 2 ml Placebo daily for days 8-21 in addition to aneurysm treatment and best medical intensive care of SAH patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>3 x 8 mg dexamethasone daily for days 1-7 and 1 x 8 mg dexamethasone daily for days 8-21</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>3 x 2 ml Saline daily for days 1-7 and 1 x 2 ml Saline daily for days 8-21</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects, equal or older than 18 years old&#xD;
&#xD;
          2. Written consent to participate in the study by the patient or his legal representative&#xD;
             (emergency inclusion by next of kin or consultant physician under the responsibility&#xD;
             of the principal investigator is possible)&#xD;
&#xD;
          3. Confirmed diagnosis of aneurysmal SAH and onset within 48 hours before inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. SAH due to any other cause than aneurysm rupture (e.g. traumatic, arteriovenous&#xD;
             malformation (AVM), fistula, dissection)&#xD;
&#xD;
          2. Any condition that, in the judgement of the Investigator, could impose hazards to the&#xD;
             patient if study therapy is initiated or affects the participation of the patient in&#xD;
             the study&#xD;
&#xD;
          3. Patients with obvious evidence of irreparable brainstem or thalamic injury&#xD;
&#xD;
          4. Patients with foreseeable difficulties to attend follow-ups adequately&#xD;
&#xD;
          5. Subjects with a physical or psychiatric condition which at the investigator's&#xD;
             discretion may put the subject at risk, may confound the trial results, or may&#xD;
             interfere with the subject's participation in this clinical trial&#xD;
&#xD;
          6. Current positive pregnancy test (e.g. β-HCG test in serum)&#xD;
&#xD;
          7. Known history of hypersensitivity to the investigational drug or to drugs with a&#xD;
             similar chemical structure&#xD;
&#xD;
          8. Severe infectious diseases&#xD;
&#xD;
          9. Known angle-closure or open angle glaucoma&#xD;
&#xD;
         10. Known ulceration in the gastro-intestinal tract&#xD;
&#xD;
         11. History of gastro-intestinal bleeding&#xD;
&#xD;
         12. Long-term treatment with corticosteroids prior SAH&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erdem Gueresir, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurosurgery, Rheinische Friedrich-Wilhelms-University of Bonn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erdem Gueresir, Prof. Dr.</last_name>
    <phone>0049 - 228 - 287 - 16518</phone>
    <email>Erdem.Gueresir@ukbonn.de</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Erdem Güresir, MD</investigator_full_name>
    <investigator_title>Prof. Dr. Erdem Güresir</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

